Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.

Bartlett JA, Fath MJ, Demasi R, Hermes A, Quinn J, Mondou E, Rousseau F.

AIDS. 2006 Oct 24;20(16):2051-64. Review.

PMID:
17053351
2.

Update of the drug resistance mutations in HIV-1: Fall 2006.

Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2006 Aug-Sep;14(3):125-30.

PMID:
16946457
3.

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society-USA panel.

JAMA. 2006 Aug 16;296(7):827-43.

PMID:
16905788
4.

A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST study.

Hales G, Birch C, Crowe S, Workman C, Hoy JF, Law MG, Kelleher AD, Lincoln D, Emery S; CREST investigators.

PLoS Clin Trials. 2006 Jul 28;1(3):e18.

PMID:
16878178
5.

Algorithms for the interpretation of HIV-1 genotypic drug resistance information.

Vercauteren J, Vandamme AM.

Antiviral Res. 2006 Sep;71(2-3):335-42. Epub 2006 May 30. Review.

PMID:
16782210
6.

Net benefits of resistance testing directed therapy compared with standard of care in HIV-infected patients with virological failure: A meta-analysis.

Ena J, Ruiz de Apodaca RF, Amador C, Benito C, Pasquau F.

Enferm Infecc Microbiol Clin. 2006 Apr;24(4):232-7.

PMID:
16725082
7.
8.

A Grid-based HIV expert system.

Sloot PM, Boukhanovsky AV, Keulen W, Tirado-Ramos A, Boucher CA.

J Clin Monit Comput. 2005 Oct;19(4-5):263-78.

PMID:
16328942
9.

Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.

Torti C, Uccelli MC, Quiros-Roldan E, Gargiulo F, Tirelli V, Lapadula G, Regazzi M, Pierotti P, Tinelli C, De Luca A, Patroni A, Manca N, Carosi G.

J Clin Virol. 2006 Apr;35(4):414-9. Epub 2005 Nov 8.

PMID:
16280255
11.

Structural analysis of reverse transcriptase mutations at codon 215 explains the predominance of T215Y over T215F in HIV-1 variants selected under antiretroviral therapy.

Yahi N, Fantini J, Henry M, Tourrès C, Tamalet C.

J Biomed Sci. 2005 Oct;12(5):701-10. Epub 2005 Nov 9.

PMID:
16200350
12.

Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.

Luis Jiménez J, Resino S, Martinez-Colom A, Bellón JM, Angeles Muñoz-Fernández M; Spanish Group of Paediatric HIV Infection.

J Antimicrob Chemother. 2005 Dec;56(6):1081-6. Epub 2005 Sep 29.

PMID:
16195257
13.

Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy.

Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, Xiang Y, Henely C, Schmetter B, Uy J, van den Berg-Wolf M, Kozal M; Terry Beirn Community Programs for Clinical Research on AIDS 058 Study Team.

Clin Infect Dis. 2005 Feb 1;40(3):468-74. Epub 2005 Jan 10.

PMID:
15668873
14.

Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen).

Saracino A, Monno L, Locaputo S, Torti C, Scudeller L, Ladisa N, Antinori A, Sighinolfi L, Chirianni A, Mazzotta F, Carosi G, Angarano G.

J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1587-98.

PMID:
15577415
15.

Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals.

Gallego O, Martin-Carbonero L, Aguero J, de Mendoza C, Corral A, Soriano V.

J Virol Methods. 2004 Oct;121(1):115-8.

PMID:
15350741
16.

Genetic correlates of efavirenz hypersusceptibility.

Shulman NS, Bosch RJ, Mellors JW, Albrecht MA, Katzenstein DA.

AIDS. 2004 Sep 3;18(13):1781-5.

PMID:
15316338
17.

Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects.

Swanstrom R, Bosch RJ, Katzenstein D, Cheng H, Jiang H, Hellmann N, Haubrich R, Fiscus SA, Fletcher CV, Acosta EP, Gulick RM; AIDS Clinical Trials Group Protocol 359 Team.

J Infect Dis. 2004 Sep 1;190(5):886-93. Epub 2004 Jul 23.

PMID:
15295692
18.

Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study.

Perez-Elias MJ, Garcia-Arota I, Muñoz V, Santos I, Sanz J, Abraira V, Arribas JR, González J, Moreno A, Dronda F, Antela A, Pumares M, Martí-Belda P, Casado JL, Geijos P, Moreno S; Realvirfen study group.

Antivir Ther. 2003 Dec;8(6):577-84.

PMID:
14760891
19.

Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.

Joly V, Descamps D, Peytavin G, Touati F, Mentre F, Duval X, Delarue S, Yeni P, Brun-Vezinet F.

Antimicrob Agents Chemother. 2004 Jan;48(1):172-5.

PMID:
14693536
20.
Items per page

Supplemental Content

Write to the Help Desk